Leptospira Medium Base, Korthof
To Order Contact us: lieven@wlsolutions.be
NBS Medium base 330mm |
||
| SHA1144 | EACH | EUR 1328.1 |
NBS Innova 44 Medium Base 330mm |
||
| SHA1112 | EACH | EUR 1377.12 |
Qual Set Base Cont Medium Range 1.0M to 3.0M |
||
| AQSB002 | 250ML | EUR 265.62 |
Tris-base |
||
| 20-abx082498 |
|
|
casting base |
||
| EHS3100-CAST | ea | EUR 128.4 |
casting base |
||
| EHS3200-CAST | ea | EUR 148.8 |
casting base |
||
| EHS3300-CAST | ea | EUR 148.8 |
Tetracycline base |
||
| GA9779-100G | 100 g | EUR 180 |
Tetracycline base |
||
| GA9779-10G | 10 g | EUR 55.2 |
Tetracycline base |
||
| GA9779-25G | 25 g | EUR 74.4 |
Rimonabant base |
||
| GX9120-10MG | 10 mg | EUR 103.2 |
Rimonabant base |
||
| GX9120-25MG | 25 mg | EUR 156 |
ProteoIQ Base |
||
| PS2 | 1 | EUR 5114.4 |
Vincamine base |
||
| Q-1435.0005 | 5.0g | EUR 270 |
|
Description: Sum Formula: C21H26N2O3; CAS# [1617-90-9] |
||
Vincamine base |
||
| Q-1435.0025 | 25.0g | EUR 963.6 |
|
Description: Sum Formula: C21H26N2O3; CAS# [1617-90-9] |
||
Positioning Base |
||
| S44I041002 | EACH | EUR 1409.04 |
Channel Base |
||
| C653 | EACH | EUR 22.46 |
Leptospira antibody |
||
| 10-1293 | 500 ug | EUR 571.2 |
|
Description: Mouse monoclonal Leptospira antibody |
||
Mounting Medium |
||
| 4300 | 3 ml | EUR 216.6 |
|
Description: This is Mounting medium (non-fading) used for maintaining optimal conditions needed to obtain the maximum fluorescence emission from Fluorescein. |
||
DC MEDIUM |
||
| D04-117-10kg | 10 kg | EUR 1894.8 |
DC MEDIUM |
||
| D04-117-2kg | 2kg | EUR 458.4 |
DC MEDIUM |
||
| D04-117-500g | 500 g | EUR 168 |
Advanced Medium |
||
| C0003-04 | RT 500 mL Bottle | EUR 123.6 |
Medium 199 |
||
| C0012-01 | RT 500 mL Bottle | EUR 126 |
COLIFORM MEDIUM |
||
| C03-127-10kg | 10 kg | EUR 1588.8 |
COLIFORM MEDIUM |
||
| C03-127-2kg | 2kg | EUR 392.4 |
COLIFORM MEDIUM |
||
| C03-127-500g | 500 g | EUR 150 |
Heller's Medium |
||
| CP014-010 | 10X1L | EUR 118.8 |
Heller's Medium |
||
| CP014-500 | 50L | EUR 151.2 |
Hoagland's Medium |
||
| CP015-010 | 10X1L | EUR 118.8 |
Hoagland's Medium |
||
| CP015-500 | 50L | EUR 151.2 |
A Medium |
||
| DJ1018 | 100g | EUR 101.76 |
EC MEDIUM |
||
| E05-100-10kg | 10 kg | EUR 976.8 |
EC MEDIUM |
||
| E05-100-2Kg | 2 Kg | EUR 259.2 |
EC MEDIUM |
||
| E05-100-500g | 500 g | EUR 114 |
NeuroProgenitor Medium |
||
| NM42400 | 125 ml | EUR 364.8 |
HLP MEDIUM |
||
| H08-107-10kg | 10 kg | EUR 2733.6 |
HLP MEDIUM |
||
| H08-107-2Kg | 2 Kg | EUR 640.8 |
HLP MEDIUM |
||
| H08-107-500g | 500 g | EUR 218.4 |
M9 Medium |
||
| SD7024 | 250g | EUR 86.1 |
M9CA Medium |
||
| SD7025 | 250g | EUR 86.1 |
YM Medium |
||
| SD7031 | 250g | EUR 84.54 |
TYGPN Medium |
||
| SD7032 | 250g | EUR 84.01 |
M63 Medium |
||
| SD7033 | 250g | EUR 86.1 |
SIM MEDIUM |
||
| S19-110-10kg | 10 kg | EUR 1225.2 |
SIM MEDIUM |
||
| S19-110-2kg | 2kg | EUR 313.2 |
SIM MEDIUM |
||
| S19-110-500g | 500 g | EUR 128.4 |
SOB MEDIUM |
||
| S19-124-10kg | 10 kg | EUR 1158 |
SOB MEDIUM |
||
| S19-124-2kg | 2kg | EUR 298.8 |
SOB MEDIUM |
||
| S19-124-500g | 500 g | EUR 124.8 |
TCBS Medium |
||
| MED1188 | PK10 | EUR 7.52 |
DNase Medium |
||
| MED1196 | PK10 | EUR 7.98 |
OF Medium |
||
| MED1664 | 500G | EUR 68.4 |
Vatalanib, Free Base |
||
| 2026-25 | EUR 366 | |
Vatalanib, Free Base |
||
| 2026-5 | EUR 151.2 | |
Erlotinib, Free Base |
||
| 2048-100 | EUR 189.6 | |
Erlotinib, Free Base |
||
| 2048-1000 | EUR 464.4 | |
Sunitinib, Free base |
||
| 2097-100 | EUR 229.2 | |
Sunitinib, Free base |
||
| 2097-1000 | EUR 601.2 | |
Sunitinib, Free base |
||
| 2097-25 | EUR 138 | |
Ruxolitinib (free base) |
||
| 10-042 | 25 mg | EUR 418.2 |
|
Description: Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. It is investigated against the spread of the SARS-CoV-2 (COVID-19). |
||
Lapatinib, Free base |
||
| 2138-100 | EUR 464.4 | |
Lapatinib, Free base |
||
| 2138-25 | EUR 229.2 | |
Ruxolitinib, Free base |
||
| 2139-100 | Ask for price | |
Ruxolitinib, Free base |
||
| 2139-25 | EUR 639.6 | |
Ruxolitinib, Free base |
||
| 2139-5 | EUR 248.4 | |
Imatinib, Free base |
||
| 2141-100 | EUR 176.4 | |
Imatinib, Free base |
||
| 2141-1000 | EUR 502.8 | |
Linsitinib, Free base |
||
| 2294-25 | EUR 679.2 | |
Linsitinib, Free base |
||
| 2294-5 | EUR 222 | |
Tipifarnib, Free base |
||
| 2296-1 | EUR 170.4 | |
Tipifarnib, Free base |
||
| 2296-5 | EUR 496.8 | |
Rucaparib (free base) |
||
| A8893-10 | 10 mg | EUR 240 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-200 | 200 mg | EUR 1243.2 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-5 | 5 mg | EUR 164.4 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-5.1 | 10 mM (in 1mL DMSO) | EUR 170.4 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
Rucaparib (free base) |
||
| A8893-50 | 50 mg | EUR 547.2 |
|
Description: Rucaparib, also named as AG-014699 or PF-01367338, is a poly (ADP ribose) polymerase (PARP) inhibitor. PARP is a DNA damage-activated nuclear enzyme that has a key signaling role in the base excision repair pathway. |
||
LY2835219 free base |
||
| A3575-100 | 100 mg | EUR 686.4 |
|
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
||
LY2835219 free base |
||
| A3575-25 | 25 mg | EUR 309.6 |
|
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
||
LY2835219 free base |
||
| A3575-5 | 5 mg | EUR 170.4 |
|
Description: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. |
||
R406 (free base) |
||
| A5880-100 | 100 mg | EUR 1452 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-25 | 25 mg | EUR 616.8 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-5 | 5 mg | EUR 199.2 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-5.1 | 10 mM (in 1mL DMSO) | EUR 316.8 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
R406 (free base) |
||
| A5880-S | Evaluation Sample | EUR 97.2 |
|
Description: R406 is a potent SYK inhibitorSpleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase mainly expressed in hematopoietic cells. It transmits signals from a variety of cell surface receptors including CD74, Fc receptor and integrins. |
||
THZ1 (Free base) |
||
| 9664-25 | EUR 1227.6 | |
THZ1 (Free base) |
||
| 9664-5 | EUR 352.8 | |
MCC950 (Free base) |
||
| B1031-1 | EUR 183.6 | |
MCC950 (Free base) |
||
| B1031-5 | EUR 548.4 | |
FIPI (free base) |
||
| B2372-25 | EUR 757.2 | |
FIPI (free base) |
||
| B2372-5 | EUR 235.2 | |
Terbinafine (Free base) |
||
| B2423-250 | EUR 248.4 | |
Terbinafine (Free base) |
||
| B2423-50 | EUR 144 | |
PLX5622 (free base) |
||
| B2965-25 | 25 mg | EUR 903.6 |
PLX5622 (free base) |
||
| B2965-5 | 5 mg | EUR 272.4 |
Apatinib (Free base) |
||
| B1613-25 | EUR 496.8 | |